There are very limited, intermittent supplies of all glucagon-like
peptide-1 receptor agonists (GLP-1 RAs).
Supplies are not expected to stabilise to meet full market demand until at least mid-2024.
The supply issues have been caused by an increase in demand for these products for licensed and off-label indications.
The off-label use of these agents for the management of obesity is strongly discouraged. Existing stock must be conserved for use in patients with diabetes. These shortages have serious clinical implications in the management of patients with type 2 diabetes.
This National Patient Safety Alert provides further background and clinical information and actions for providers.
*** 28 September 2023: the original alert pdf has been updated to amend the wording
under action 3. i. to refer to NICE NG28. This replaces the incorrect reference
to NICE CG28 in the original pdf. No other changes have been made.***